Sapphire Biotech scientists have developed a new lateral flow assay test to measure the enzyme QSOX1 that is found to be elevated in subjects with pancreatic cancers. The purpose of the trial is to evaluate the diagnostic potential of Sapphire’s lateral flow assay to detect QSOX1 in patients with or at risk for pancreatic cancer. There is currently no blood test that allows for early detection of pancreatic cancer. Certain substances, such as carcinoembryonic antigen (CEA) and CA 19-9, are elevated in people with pancreatic cancer. However, blood tests don’t allow for early detection of pancreatic cancer, because these levels may not rise until pancreatic cancer is advanced.
About Sapphire Biotech
Sapphire Biotech was founded in 2019 to create novel Therapeutic approaches for cancer. Additionally, Sapphire plans to develop novel Diagnostics for early cancer detection, one of which is currently being evaluated in a clinical trial for its potential to diagnose pancreatic cancer. The company is currently formulating small molecules that target QSOX1, a master regulator of extracellular matrix and related secreted proteins. Located in San Diego, CA, Sapphire Biotech is privately held. For more information, please visit www.sapphirebiotech.com.